Patient characteristics and results (n = 103 patients)
| Characteristic . | Value . |
|---|---|
| Patient median age, y (range) | 55 (32-68) |
| Donor median age, y (range) | 42 (17-69) |
| Sex of patient, M/F | 62/41 |
| Sex of donor, M/F | 65/38 |
| PMF | |
| Primary | 63 |
| Post-PV/ET | 40 |
| Median time for diagnosis to SCT, mo (range) | 19 (3-276) |
| Risk profile according to Lille score | |
| Low | 17 |
| Intermediate | 55 |
| High | 31 |
| Risk profile according to Cervantes score | |
| Low | 23 |
| High | 76 |
| Unknown | 4 |
| Spleen size before stem cell transplantation | |
| Enlarged | 80 |
| Not enlarged | 8 |
| Splenectomy | 14 |
| Unknown | 1 |
| JAK2 V617F mutation status | |
| Positive | 59 |
| Negative | 23 |
| Unknown | 21 |
| Cytogenetics | |
| Abnormal | 29 |
| Normal | 37 |
| Unknown | 37 |
| HLA matching (10/10 allele) | |
| Matched | 82 |
| Mismatched | 21 |
| HLA-identical sibling | 33 |
| Matched unrelated donor | 70 |
| Stem cell source | |
| Bone marrow | 3 |
| Peripheral blood stem cells | 99 |
| Peripheral blood stem cells plus bone marrow | 1 |
| Median no. of CD34+ infused stem cells/kg BW (range) | 6.8 × 106 (0.7-21.7) |
| CMV serostatus of recipients | |
| Positive | 47 |
| Negative | 55 |
| Unknown | 1 |
| Fibrosis grading (n = 73) | |
| Grade 0 | 2 |
| Grade 1 | 6 |
| Grade 2 | 28 |
| Grade 3 | 37 |
| Primary graft failure | 2 (2%) |
| Median leukocyte engraftment (NC > 1.0 × 109/L), days (range) | 18 (10-84) |
| Median platelet engraftment (platelet > 20 × 109/L), days (range) | 22 (8-145) |
| Toxicity grade 3 or 4 | |
| Liver | 10% |
| Acute GVHD | |
| Grade 0 to 1 | 74% |
| Grade 2 to 4 | 26% |
| Grade 3 or 4 | 11% |
| Chronic GVHD | |
| Limited | 24% |
| Extensive | 24% |
| Veno-occlusive disease (n = 93) | |
| None | 80% |
| Mild | 7% |
| Moderate | 11% |
| Severe | 2% |
| Response | |
| Complete histo-hematologic | 44 |
| Partial histo-hematologic | 3 |
| Treatment failure | 11 |
| Missing or unclear | 45 |
| Characteristic . | Value . |
|---|---|
| Patient median age, y (range) | 55 (32-68) |
| Donor median age, y (range) | 42 (17-69) |
| Sex of patient, M/F | 62/41 |
| Sex of donor, M/F | 65/38 |
| PMF | |
| Primary | 63 |
| Post-PV/ET | 40 |
| Median time for diagnosis to SCT, mo (range) | 19 (3-276) |
| Risk profile according to Lille score | |
| Low | 17 |
| Intermediate | 55 |
| High | 31 |
| Risk profile according to Cervantes score | |
| Low | 23 |
| High | 76 |
| Unknown | 4 |
| Spleen size before stem cell transplantation | |
| Enlarged | 80 |
| Not enlarged | 8 |
| Splenectomy | 14 |
| Unknown | 1 |
| JAK2 V617F mutation status | |
| Positive | 59 |
| Negative | 23 |
| Unknown | 21 |
| Cytogenetics | |
| Abnormal | 29 |
| Normal | 37 |
| Unknown | 37 |
| HLA matching (10/10 allele) | |
| Matched | 82 |
| Mismatched | 21 |
| HLA-identical sibling | 33 |
| Matched unrelated donor | 70 |
| Stem cell source | |
| Bone marrow | 3 |
| Peripheral blood stem cells | 99 |
| Peripheral blood stem cells plus bone marrow | 1 |
| Median no. of CD34+ infused stem cells/kg BW (range) | 6.8 × 106 (0.7-21.7) |
| CMV serostatus of recipients | |
| Positive | 47 |
| Negative | 55 |
| Unknown | 1 |
| Fibrosis grading (n = 73) | |
| Grade 0 | 2 |
| Grade 1 | 6 |
| Grade 2 | 28 |
| Grade 3 | 37 |
| Primary graft failure | 2 (2%) |
| Median leukocyte engraftment (NC > 1.0 × 109/L), days (range) | 18 (10-84) |
| Median platelet engraftment (platelet > 20 × 109/L), days (range) | 22 (8-145) |
| Toxicity grade 3 or 4 | |
| Liver | 10% |
| Acute GVHD | |
| Grade 0 to 1 | 74% |
| Grade 2 to 4 | 26% |
| Grade 3 or 4 | 11% |
| Chronic GVHD | |
| Limited | 24% |
| Extensive | 24% |
| Veno-occlusive disease (n = 93) | |
| None | 80% |
| Mild | 7% |
| Moderate | 11% |
| Severe | 2% |
| Response | |
| Complete histo-hematologic | 44 |
| Partial histo-hematologic | 3 |
| Treatment failure | 11 |
| Missing or unclear | 45 |
SCT indicates stem cell transplantation; CMV, cytomegalovirus; and NC, neutrophil count.